Summary
In a cooperative study of the Japanese Urological Cancer Research Group for Adriamycin, the usefulness of chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin (M-VAC therapy) in treating advanced or recurrent bladder cancer was examined. Evaluation of the clinical responses obtained in 86 evaluable patients revealed 13 complete responses, 29 partial responses, 4 minor responses, 19 cases of no change, and 21 cases of progressive disease. The overall response rate was 48.8% (42/86). The rate of response to M-VAC therapy at each disease site was as low as 21.4% (3/14) in bone lesions but exceeded 40% in the primary lesion, the lymph nodes, the lung, the liver, and other lesions. The clinical response to M-VAC therapy was not significantly influenced by the performance status of the patients, the dose intensity, or previous therapy. The median duration of response for the 42 responders was 22.7 weeks (range, 8.1–134.1 weeks), and the median duration of survival for the 86 evaluable patients was 9.8 months. Side effects were frequently encountered; the patients experienced anorexia, nausea, vomiting, malaise, alopecia, and leukopenia, but all of these symptoms were tolerable.
Similar content being viewed by others
References
Green JA, Dawson AA, Fell LF, Murray S (1980) Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. Br J Clin Pharmacol 9: 511
Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281
Maru A, Akaza H, Isaka S, Koiso K, Kotake T, Machida T, Matsumura Y, Nakagami Y, Niijima T, Obata K, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, Uyama T, the Japanese Urological Cancer Research Group for Adriamycin (1987) Phase III trial of the Japanese Urological Cancer Research Group for Adramycin: cyclophosphamide, Adriamycin, and cisplatin versus cyclophosphamide, Adriamycin, and 5-fluorouracil in patients with advanced transitional-cell carcinoma of the urinary bladder. Cancer Chemother Pharmacol 20 [Suppl]: S44
Smalley RV, Bartolucci AA, Hemstreet G, Hester M (1981) A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 125: 191
Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, Morse MJ, Whitmore WF (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403
Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan DE Jr, Bander N, Weiselberg LR, Geller N, Hollander PS, Lipperman R, Fair WR, Whitmore WF Jr (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461
Troner MB, Hemstreet GP III (1981) Cyclophosphamide, doxorubicin and cisplatin (CAP) in the treatment of urothelial malignancy: a pilot study of the Southeastern Cancer Group. Cancer Treat Rep 65: 29
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Kotake, T., Akaza, H., Isaka, S. et al. Evaluation of systemic chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin for advanced bladder cancer. Cancer Chemother. Pharmacol. 30 (Suppl 1), S85–S89 (1992). https://doi.org/10.1007/BF00686950
Issue Date:
DOI: https://doi.org/10.1007/BF00686950